Early-Stage Startup Challenges: Diagnose Before You Act

“We need to move faster” is one of the least useful sentences in an early-stage company.

It can mean that product discovery is circling. It can mean that a founder is still the only person able to onboard a customer. Or it can mean that the team is about to promise work it does not yet understand.

Those situations may feel alike because each produces delay. They do not have the same cause, and they should not receive the same response.

A hiring sprint will not resolve uncertainty about buyer behaviour. Another customer interview will not remove a regulatory dependency. A tighter roadmap will not fix a product whose value is still unclear.

The useful question is not “What challenges do startups face?” It is “Which constraint could invalidate the next consequential decision, and what kind of uncertainty surrounds it?”

That shift turns a familiar list of startup problems into a diagnosis.

A challenge list is not a diagnosis

Lists of early-stage problems have a comforting shape: funding, hiring, focus, sales, retention, technical debt. The categories are real. Their order is not.

The problem that attracts the most complaints is not necessarily the one constraining the venture. A noisy sales pipeline can hide weak activation. A slow engineering team can be waiting on unresolved commercial choices.

Stage matters too, but not as a deterministic label.

Wang and colleagues studied this in a 2016 survey of software startups.

They cleaned 8,240 raw responses to 4,100 operating, named, de-duplicated companies.

Respondents selected their three biggest recent problems from a predefined list and classified their learning and product-development stage.

The frequency tables and chi-square tests found that reported challenges differed by self-described stage. That supports a modest conclusion: a priority that made sense earlier should not survive by habit alone.

It does not identify any company’s binding constraint. The data are cross-sectional perceptions, not observed causes or outcomes. Stages were self-selected, and the firms were software startups.

Of the 3,613 firms that disclosed a location, 51.3% were in the United States. That concentration further limits how confidently the reported pattern travels to other ecosystems.

Use stage-based lists to widen the scan. Do not use them to close the diagnosis.

Start with the decision that could become expensive

An abstract diagnosis expands without limit. Anchor it to a decision the company may soon struggle to reverse.

That might be a contract with bespoke obligations, a new market entry, a senior hire, a platform rewrite, or a promise that changes the product for every customer.

Write the decision in one sentence. Then ask what would have to be true for it to remain sensible.

This makes vague concern inspectable.

“Enterprise is difficult” becomes several claims: the buyer values the workflow, security review is feasible, implementation cost is tolerable, and the product can support the promised configuration.

The point is not to calculate a perfect business case. Early-stage evidence rarely supports one. The point is to expose which assumption can overturn the decision and which merely affects its convenience.

Reversibility helps set the depth of diagnosis. A week-long manual test can proceed with rough evidence. A multi-year contractual commitment deserves more scrutiny because the loss is harder to contain.

This is also where generic urgency loses its power. Speed is useful only after the team knows what it is trying to learn, protect, or commit.

Split the situation into subproblems

An aggregate label such as “go-to-market risk” is too broad to act on. It combines questions whose evidence, owners, and response modes differ.

Loch, Solt and Bailey made that separation central to their study of unforeseeable uncertainty in a new venture.

Their evidence came from one participant-observer case: the turnaround of enterprise-software startup Escend Technologies.

Bailey, the company’s CEO, was a coauthor. The academic coauthors met with her, reviewed internal and external company documents and status reports, and kept detailed notes during the turnaround.

The authors decomposed the venture situation into subproblems, assessed the knowledge gaps around each, and considered whether a subproblem was vulnerable to events the team could not foresee.

That move is useful because uncertainty is rarely uniform. Customer access may be understood while implementation effort is not. Pricing may be testable while a regulatory interpretation requires outside expertise.

The study does not establish a universal method. It is one distressed enterprise-software case with the CEO participating in the research. It cannot show that the process causes survival or transfers unchanged to other settings.

It also warns against treating diagnosis as clerical work. Decomposition requires judgement, consumes attention, and has to change when new information alters the situation.

For a working team, the immediate task is simpler: replace the single complaint with distinct subproblems that can be evidenced and owned.

Name the uncertainty before choosing the response

Teams often describe every unknown as “risk.” That collapses important differences.

Some facts are known: a contract contains a specific clause, an integration uses a documented protocol, or the company has eight weeks of cash. These call for execution, not experimentation.

Some outcomes are uncertain, but their range and drivers can be estimated from relevant evidence. This is risk in the narrower sense. Plans, buffers and explicit contingencies can help.

Some gaps are known but not yet measured. A buyer’s willingness to change a workflow fits here. A focused interview, prototype or commercial test may reduce the gap.

Other subproblems are vulnerable to unforeseeable uncertainty. The team does not merely lack an answer; it may not yet know which variable will matter. A detailed forecast can create confidence without adding knowledge.

Complexity is a separate dimension. Even familiar components can produce surprising behaviour when dependencies are dense and changes propagate across the system.

Do not force these labels into false precision. Their value lies in preventing the automatic use of the same response for every uncomfortable unknown.

Match the response to the uncertainty

Planning is appropriate when the relevant variables are sufficiently known and the team can estimate exposure. Define the decision rules, assign ownership and protect against identifiable failure modes.

When the important gap can be reduced sequentially, use a probe that can change the next decision. The probe should expose the uncertain assumption, not produce activity that merely looks empirical.

Parallel trials are a narrower option. They can help when several approaches must be explored before the company can know which one works, but only if the venture can afford them and compare them on meaningful evidence.

Sommer, Loch and Dong tested these distinctions in a study of 58 startups in Shanghai.

Their survey and regression analysis related planning, trial-and-error learning and selectionism through parallel trials to reported performance under different levels of complexity and unforeseeable uncertainty.

The findings did not support one response for every condition. Planning fitted lower uncertainty and complexity; learning became more relevant under unforeseeable uncertainty.

Parallel trials depended on stricter conditions, including whether selection could wait until real market performance became observable.

The result is conditional evidence, not a recipe. The study is observational, self-reported, based in one ecosystem and small at 58 companies. It cannot establish that a response mode caused performance.

Parallel trials can also consume a startup’s scarce people, customer access and cash. “Run several bets” is poor advice when the company cannot sustain or fairly compare them.

There is one more case: useful inputs may be unknowable before other people commit.

Read and colleagues used concurrent verbal protocols to compare 27 expert entrepreneurs with 37 managers who had little entrepreneurial expertise.

All 64 participants thought aloud through the same hypothetical, unpredictable marketing problem. The groups used different heuristics.

The experts more often used nonpredictive, effectual logic and worked with stakeholder commitments to construct possible market paths, rather than trying only to forecast an existing market.

This is not evidence that instinct beats analysis. The study used an artificial case and nonequivalent, nonrandomised groups. It cannot show that experience caused the strategy or that the strategy improves venture outcomes.

The practical inference is narrower than the study: when useful inputs do not exist yet, a bounded commitment from a real stakeholder may reveal more than another forecast.

Use a constraint register without turning it into theatre

The register below is a practical synthesis for this article, not a validated research instrument.

Its purpose is to keep different subproblems from collapsing back into one urgent story.

• Subproblem: the smallest useful statement of what is constrained.
• Decision it can invalidate: the commitment that makes this relevant now.
• Observed evidence: facts, behaviour or records rather than interpretations.
• What is known: conditions the team can treat as stable for this decision.
• What remains unknown: gaps that could change the choice.
• Uncertainty type: known fact, estimable risk, known gap, unforeseeable exposure or complexity.
• Dependencies: other decisions or systems that can amplify the issue.
• Loss if wrong: time, cash, trust, legal exposure or strategic lock-in.
• Response mode: plan, protect, investigate, probe, seek expertise or defer.
• Owner: the person accountable for the next information-producing action.
• Next information point: the evidence that can alter the decision.
• Review trigger: the event that makes the current diagnosis stale.

A register is useful only if it changes a decision. A full table that preserves the roadmap exactly as it was is documentation, not diagnosis.

Keep observed evidence separate from interpretation. “Three buyers asked for SSO” is evidence. “Enterprise demand is proven” is a claim that still carries assumptions about budget, urgency and adoption.

Make the response mode explicit. Otherwise teams default to their favourite capability: product teams build, sales teams call, operators add process, and founders escalate urgency.

Look for coupling, not only severity

The most painful item is not always the binding one. A constraint matters because of what it blocks and what it can cause downstream.

A manual onboarding step may look operationally minor. If every enterprise sale requires founder involvement, however, it couples revenue, product learning and leadership capacity to one person’s calendar.

Conversely, a serious engineering weakness may not constrain the next decision if the company can isolate it behind a manual service for the next test.

Map the dependency chain around the decision. Which subproblem must be resolved first? Which can be contained? Which becomes dangerous only when combined with another commitment?

This prevents “highest severity” from becoming another generic ranking exercise. The binding constraint is the one that can stop, distort or make the next consequential choice unexpectedly expensive.

A fictional enterprise commitment

Consider a fictional B2B startup that helps regulated companies coordinate compliance work. A prospective customer wants an implementation date written into the contract.

The team’s initial diagnosis is that shipping is too slow. That statement bundles four different subproblems.

First, the customer needs an audit export in a documented format. The requirement is known, the technical work can be estimated, and ordinary planning fits.

Second, users may resist a changed approval workflow. The gap is known but behavioural. A realistic workflow test with intended users can reduce it.

Third, the contract assumes a particular interpretation of a new regulation. A product experiment cannot settle that question. The company needs qualified legal or domain expertise and a boundary on what it will promise.

Fourth, the founder remains the only person who can configure a customer account. That is an operating-capacity constraint, not evidence that the product team lacks velocity.

The decision under review is not “Can the team ship faster?” It is “Should the company promise implementation before the regulatory obligation and support burden are understood?”

The register gives each subproblem an owner and response mode. Engineering estimates the export. Product investigates workflow acceptance. Counsel clarifies the obligation. Operations documents founder-only work.

The review trigger is the first of three events: counsel resolves the interpretation, the workflow test contradicts the assumed process, or the support estimate exceeds the contract’s acceptable exposure.

No outcome is implied here. The example shows only how one urgent complaint becomes a set of decisions that can be examined on their own terms.

Reopen the diagnosis when the situation changes

An early-stage constraint is not a permanent company trait. It can move after a large customer commits, a regulation changes, a cofounder leaves, or an experiment closes one uncertainty and exposes another.

Revisit the register when evidence invalidates an assumption or a new commitment changes the cost of being wrong. A weekly ceremony is unnecessary if nothing material has changed.

Equally, do not let a quarterly planning cycle delay a diagnosis that is already stale.

The discipline is to preserve the chain from evidence to uncertainty, from uncertainty to response, and from response to the decision it is meant to improve.

An early-stage company often has more active problems than available capacity. The advantage comes from knowing which problem can invalidate the next serious commitment—and refusing to answer it with the wrong kind of work.

Sources

• Loch, C. H., Solt, M. E., & Bailey, E. M. (2008). Diagnosing Unforeseeable Uncertainty in a New Venture. Journal of Product Innovation Management, 25(1), 28–46. One participant-observer case; useful for decomposition, not causal or generalisable claims.
• Sommer, S. C., Loch, C. H., & Dong, J. (2009). Managing Complexity and Unforeseeable Uncertainty in Startup Companies: An Empirical Study. Organization Science, 20(1), 118–133. Survey and regression evidence from 58 Shanghai startups.
• Wang, X., Edison, H., Bajwa, S. S., Giardino, C., & Abrahamsson, P. (2016). Key Challenges in Software Startups Across Life Cycle Stages. XP 2016, LNBIP 251. Cross-sectional survey of 4,100 software startups after data cleaning.
• Read, S., Dew, N., Sarasvathy, S. D., Song, M., & Wiltbank, R. (2009). Marketing under Uncertainty: The Logic of an Effectual Approach. Journal of Marketing, 73(3), 1–18. Concurrent verbal protocols from 27 expert entrepreneurs and 37 managers.

Read next

• How Startups Excel at Lean MVP — stage commitments so learning does not consume the runway.
• Scaling Startup Velocity from Day One — inspect delays between a decision and the evidence needed to revise it.
• Rethinking Product-Market Fit for Modern Products — examine fit by segment and use case instead of treating it as a company-wide state.
• Fundraising Strategy: Decide What Capital Must Buy — decide whether external capital fits the constraint and what evidence the round must fund.